Clinical trials: Corticosteroid Injection
Rhinitis, Allergic, Perennial
A Study of GW685698X for the Treatment Of Perennial Allergic Rhinitis in Adolescents and Adults
The purpose of this study is to assess the effect of an aqueous nasal spray investigational compound compared to placebo on the hypothalamic pituitary adrenocortical (HPA) axis system in adolescents and adults 12 to 65 years of…
- Trial name
- NCT00116818
- Testing
- GW685698X aqueous nasal spray
- Where
- 2 sites in United States, Canada
- Volunteers
- 90 people
- Sponsor
- GlaxoSmithKline
Fuchs' Dystrophy, Bullous Keratopathy
Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)
The purpose of this study is to compare two different commonly used steroid dosing regimens after Descemet's membrane endothelial keratoplasty (DMEK) transplant surgery.
- Trial name
- NCT01448213
- Testing
- Prednisolone acetate, Fluorometholone
- Where
- 2 sites in United States, Germany
- Volunteers
- 264 people
- Sponsor
- Price Vision Group
Pulmonary Disease, Chronic Obstructive
Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2
After screening, subjects will enter a 4 week open-label run-in period with fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg administered once daily via dry powder inhaler (DPI).
- Trial name
- NCT02119286
- Testing
- FF, VI, UMEC
- Where
- 57 sites in United States, Czechia and 2 more
- Volunteers
- 620 people
- Sponsor
- GlaxoSmithKline
Asthma
Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone
The aim of this study is to assess and compare efficacy and safety of BI 54903 at doses of very low dose twice daily (b.i.d) and low dose once daily (evening dosing) and placebo over an 12-week treatment period in asthmatic…
- Trial name
- NCT01458886
- Testing
- BI 54903 MD, BI 54903
- Sponsor
- Boehringer Ingelheim
Takayasu Arteritis (TAK)
A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)
The main objective of this study is to evaluate the efficacy of upadacitinib in combination with a corticosteroid taper regimen compared to placebo in combination with a corticosteroid taper regimen.
- Trial name
- SELECT-TAK (NCT04161898)
- Testing
- Upadacitinib, Prednisolone
- Where
- 48 sites in Argentina, Brazil and 4 more
- Volunteers
- 56 people
- Sponsor
- AbbVie
Healthy
Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate
The purpose of this study is to test the body's response to several doses of two different inhalation products in healthy volunteers.
- Trial name
- NCT02232087
- Testing
- Salmeterol, fluticasone propionate
- Where
- United Kingdom
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Kindeva Drug Delivery
Asthma
A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist
The purpose of this study is to continue to characterize the safety profile of benralizumab administration and monitor the pharmacodynamic activity of the drug in those asthma patients who remain on treatment for at least 16…
- Trial name
- MELTEMI (NCT02808819)
- Testing
- Benralizumab
- Where
- 178 sites in United States, Argentina and 13 more
- Volunteers
- 447 people
- Sponsor
- AstraZeneca
Asthma
Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy
The aim of the study is to assess and compare efficacy and safety of BI 54903 at 3 doses twice daily (b.i.d.) and fluticasone propionate hydrofluoroalkane metered dose inhaler (HFA MDI) at a dose of 88 mcg b.i.d and placebo…
- Trial name
- NCT01397162
- Testing
- Fluticasone propionate, BI 54903
- Where
- 41 sites in United States
- Volunteers
- 29 people
- Sponsor
- Boehringer Ingelheim
Osteoarthritis of the Knee
Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee
The purpose of this study was to assess the safety and efficacy of FX006 for the treatment of pain in patients with osteoarthritis of the knee.
- Trial name
- NCT02357459
- Testing
- FX006, TCA IR 40
- Where
- 38 sites in United States, Australia and 6 more
- Volunteers
- 486 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Asthma
A Single-dose, Randomised, Crossover, Placebo-controlled Study Assessing Two Fixed-dose Combinations of Inhaled Long-acting Beta-agonist and Corticosteroid
The purpose of this study is to assess the the ability of a single dose of LAS40468 administered via Genuair® and a single dose of salmeterol/fluticasone propionate (Seretide®) administered via Accuhaler to produce…
- Trial name
- NCT02094274
- Testing
- LAS40468, Salmeterol/fluticasone propionate
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Almirall, S.A.
Asthma
Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.
To investigate the efficacy of ciclesonide MDI either as once daily or twice daily in patients with mild to moderate asthma, who have not previously been treated with an inhaled corticosteroid.
- Trial name
- NCT00174720
- Testing
- Ciclesonide (XRP1526)
- Where
- 11 sites in United States, Brazil and 9 more
- Volunteers
- 708 people
- Sponsor
- Sanofi
Colitis, Hepatitis
PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure
Extracorporeal photopheresis (ECP) is an immunomodulatory therapy in which the photoactivating agent methoxsalen (also known as UVADEX) is used in combination with ultraviolet A (UVA) light.
- Conditions
- Colitis, Hepatitis, Melanoma (Skin Cancer)
- Trial name
- PHOENIX-ECP (NCT07619898)
- Testing
- methoxsalen, Extracorporeal photopheresis (ECP), Vedolizumab
- Volunteers
- 112 people
- Sponsor
- Therakos LLC
Bullous Pemphigoid
Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)
A phase III two-part study of nomacopan, a bifunctional inhibitor of complement component C5 and leukotriene B4 (LTB4), for the treatment of moderate and severe bullous pemphigoid.
- Trial name
- ARREST-BP (NCT05061771)
- Testing
- nomacopan (rVA576)
- Where
- 12 sites in United States, Germany and 2 more
- Sponsor
- AKARI Therapeutics
Asthma
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age
The primary objective of this study is to evaluate the efficacy and safety of adding GSK2190915 100mg, GSK2190915 300mg or placebo tablets administered once daily to fluticasone propionate 100mcg inhalation administered twice…
- Trial name
- NCT01156792
- Testing
- FP 100, GSK2190915 100, GSK2190915 300
- Where
- 32 sites in United States
- Volunteers
- 162 people
- Sponsor
- GlaxoSmithKline
Hypereosinophilia, Hypereosinophilic Syndrome
Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)
Hypereosinophilic syndrome (HES) is a rare disease with broad clinical signs and symptoms which is diagnosed based on a persistent blood eosinophil count of greater than 1500 cells, various end-organ damages (including skin…
- Trial name
- NCT00086658
- Testing
- mepolizumab
- Where
- 29 sites in United States, Australia and 6 more
- Volunteers
- 86 people
- Sponsor
- GlaxoSmithKline
Diabetic Macular Edema
Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
Evaluation of safety and tolerability of a single injection of NOVA63035 "Corticosteroid" administered at one of four doses in patients with diabetic macular edema (DME) secondary to diabetic retinopathy
- Trial name
- NCT00665106
- Testing
- NOVA63035 "Corticosteroid"
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Santen SAS
Seasonal Allergic Rhinitis
Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid
The purpose of this study is to compare the efficacy of Olopatadine Nasal Spray with Azelastine Nasal Spray when treatments are utilized in conjunction with Fluticasone Nasal Spray for the treatment of seasonal allergic rhinitis.
- Trial name
- NCT00845195
- Testing
- Olopatadine HCl Nasal Spray, 0.6%, Azelastine HCl Nasal Spray, 0.1%
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Alcon Research
Asthma
Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)
The CHRONICLE Study is a multi-center, non-interventional, prospective cohort study of adults with severe asthma who do not achieve control with high-dose inhaled corticosteroid (ICS) therapy with additional controllers and/or…
- Trial name
- NCT03373045
- Where
- 175 sites in United States, Puerto Rico
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Asthma
A Study to Measure Serum Periostin, Asthma-Related Biomarkers and Response to Prednisolone in Adult and Adolescent Patients With Severe Oral Corticosteroid-Dependent Asthma
This interventional, open study will evaluate clinical data in relation to biomarkers in patients 12 to 75 years of age with severe oral corticosteroid (OCS) - dependent asthma.
- Trial name
- NCT01948401
- Testing
- LABA, corticosteroids, prednisolone
- Where
- 11 sites in United Kingdom
- Volunteers
- 54 people
- Sponsor
- Hoffmann-La Roche
Pemphigus Vulgaris (PV)
A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
This study was designed to assess the efficacy and safety of CellCept (1 g or 1.5 g orally twice daily for 52 weeks) in patients with pemphigus vulgaris receiving prednisone or other corticosteroids.
- Trial name
- NCT00683930
- Testing
- Mycophenolate Mofetil 2 g/Day, Mycophenolate Mofetil (MMF) 3 g/Day
- Where
- 26 sites in United States, Canada and 6 more
- Volunteers
- 96 people
- Sponsor
- Hoffmann-La Roche